Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

Abstract CDK4/6 inhibitors (CDK4/6i) improve outcomes for estrogen receptor (ER) positive/HER2-negative breast cancers (BCs), yet intrinsic and acquired resistance exist. Here, we evaluated anastrozole in combination with palbociclib (ANA/PAL) in the NeoPalAna Endocrine-Resistant cohort (NCT01723774...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Tim Kong, Alex Mabry, Maureen Highkin, Anthony Z. Wang, Jeremy Hoog, Zhanfang Guo, Adrian Gonzales-Gonzales, Shana Thomas, Yingduo Song, Feng Gao, Mateusz Opyrchal, Lindsay Peterson, Foluso Ademuyiwa, Julie Margenthaler, Rebecca Aft, Katherine Glover-Collins, Leslie Nehring, Yu Tao, Souzan Sanati, Ian S. Hagemann, Fouad Boulos, Matthew Holt, Li Ding, Wenge Zhu, Stephen T. Oh, Jianxin Wang, Agnieszka K. Witkiewicz, Erik S. Knudsen, Ron Bose, Jason D. Weber, Matthew Goetz, Donald Northfelt, Jingqin Luo, Cynthia X. Ma
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Portfolio 2026-01-01
سلاسل:	Nature Communications
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41467-026-68570-6
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!